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INTRODUCTION
Celiac disease (CD) is an immune mediated condition
that results from a reaction to dietary gluten and primarily
affects the small intestine. Genetically predisposed
individuals develop a chronic inflammatory state of the
small intestine which leads to malabsorption. The disease
is mediated by HLA DQ2 or DQ8 haplotypes, which bind
the gliadin peptides of gluten, present the peptides to
CD4+ T lymphocytes and trigger cytokine and B
lymphocyte responses.1
The prevalence of CD in the United States is approximately
1% and can reach up to 4-5% in at-risk groups.2 Serologic
study of asymptomatic elderly patients in the United
Kingdom revealed a 1% prevalence rate of CD. The
diagnosis of CD can be challenging in those without the
classic malabsorptive symptoms of chronic diarrhea and
bloating. Patients with silent CD vary in their presentation.
In some cases, the diagnosis is made after a patient
presents with iron deficiency anemia, osteoporosis, or an
incidental finding of duodenal villous atrophy on
endoscopy.3,4 Additionally, undiagnosed CD can increase
long term risk of lymphoma, infertility, miscarriage, and
complications in pregnancy.5,6 Mothers with untreated
active CD are at higher risk of preterm labor, small for
gestational age, or low birthweight infants.6 This case
reinforces the importance of recognizing atypical
presentations of CD in pregnancy to prevent maternal
and fetal complications due to active disease.

CASE PRESENTATION
A 28-year-old G1P0 female of Italian and Irish descent
with no prior medical history presented to her obstetrician
at 15 weeks gestation with asymptomatic hypertension
and transaminase elevation. Pertinent physical exam
findings included gravid abdomen and trace pitting
edema of the lower extremities. Laboratory data were
significant for AST and ALT of 52 and 42, respectively.
These values increased to AST and ALT of 221 and 203
at 30 weeks gestation and remained in the 100-200
range for the remainder of her pregnancy.
The differential diagnosis for the patient’s transaminase
elevation included pre-eclampsia, HELLP syndrome,
intrahepatic cholestasis of pregnancy, acute fatty liver of
pregnancy, autoimmune hepatitis, Wilson's Disease, CD,
hereditary hemochromatosis, and nonalcoholic fatty
liver disease. Initial workup for transaminase elevation
was remarkable only for hepatic steatosis on abdominal
ultrasound, with normal liver size, echogenicity and
echotexture. Iron studies were consistent with iron

deficiency anemia. Serologic testing for etiologies of
transaminase elevation including hepatitis A, hepatitis B,
hepatitis C, auto-immune hepatitis, primary biliary
cholangitis, Wilson’s disease, and alpha-1 anti-trypsin
deficiency were unremarkable. The patient was
diagnosed with chronic hypertension and transaminase
elevation secondary to superimposed preeclampsia. She
delivered a 2850 gram female at gestational age of
37w1d. The patient’s transaminases remained elevated
up to three times the upper limit of normal post-partum
which prompted re-evaluation. In addition to repeat
testing for the aforementioned viral, auto-immune, and
inherited causes of transaminase elevation, a Celiac
antibody panel including endomysial antibody IgA,
anti-tissue transglutaminase antibody (IgA tTG), and
immunoglobulins was checked. She was ultimately
found to have weakly IgA tTG of 6 units/mL (upper limit
of n o r m a l is 3 ). B i o ps y at t h e t i m e of
esophagogastroduodenoscopy (EGD) revealed
duodenal mucosa with intraepithelial lymphocytosis and
focal moderate villous blunting which met Marsh 3b
criteria for CD. She was started on a gluten free diet with
subsequent normalization of her transaminase levels.

DISCUSSION
There is an established connection between active CD
and potential reproductive health repercussions including
unexplained infertility, miscarriage, fetal growth restriction,
delayed menarche, early menopause and secondary
amenorrhea.7-13 Adherence to a strict gluten free diet has
also been shown to curtail risk of fetal growth restriction,
infertility and miscarriage. 14 There are two leading
hypotheses for the pathogenesis of adverse pregnancy
outcomes in CD. One hypothesis is an antibody mediated
process inferred by the close link between CD activity and
reproductive failure. Potential mechanistic models have
been proposed based on in vitro studies. The first is direct
binding of anti-TG antibodies to trophoblasts of the
embryo resulting in apoptosis and impaired trophoblast
invasion.15 The second is anti-tTG antibodies inhibiting
maternal endometrial angiogenesis by impairing the
cytoskeleton structure of endometrial endothelial cells.16
Another hypothesis is based on an association between
an increased rate of spontaneous abortion and certain
vitamin and mineral deficiencies which have increased
prevalence in CD.
Pregnancy and the postpartum period have a profound
effect on autoimmune disorders transcending CD. The
mechanism driving this is unclear. It has been proposed
that pregnancy causes dysregulation of certain populations
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of T-helper cells to allow for tolerance of paternal antigens
introduced by the fetus. This is mediated by an increase in
T-helper 2 type cells (Th2) over T-helper 1 type cells (Th1).
Autoimmune diseases that are predominately Th1
regulated can improve in pregnancy, while those that are
Th2 mediated may be exacerbated. 21 Celiac disease is a
Th1 mediated disease, therefore pregnancy may make
detecting antibodies and successfully diagnosing the
disease more challenging.22
Given the implications of CD in several obstetric and
gynecologic disorders, it’s imperative to address how and
who should be tested. The gold standard for diagnosing
CD includes positive serology confirmed by duodenal
biopsy via an upper gastrointestinal endoscopy. The
spectrum of histological changes seen in the small
intestinal architecture are categorized using Marsh’s classification system. 23 However, given the risks of sedation,
pregnancy is a relative contraindication to endoscopy.
Thus, screening for celiac disease antepartum would
occur with serological tests with postpartum endoscopy
to confirm the diagnosis.
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